USA - NYSE:ZBH - US98956P1021 - Common Stock
The current stock price of ZBH is 103.03 USD. In the past month the price increased by 4.88%. In the past year, price increased by 0.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.47 | 195.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.02 | 53.26B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B |
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
ZIMMER BIOMET HOLDINGS INC
345 E Main St
Warsaw Indiana INDIANA 46580 US
CEO: Bryan Hanson
Employees: 17000
Phone: 15742676131
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
The current stock price of ZBH is 103.03 USD. The price decreased by -0.13% in the last trading session.
ZIMMER BIOMET HOLDINGS INC (ZBH) has a dividend yield of 0.97%. The yearly dividend amount is currently 0.97.
ZBH has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
ZBH stock is listed on the New York Stock Exchange, Inc. exchange.
ZIMMER BIOMET HOLDINGS INC (ZBH) has a market capitalization of 20.41B USD. This makes ZBH a Large Cap stock.
The outstanding short interest for ZIMMER BIOMET HOLDINGS INC (ZBH) is 3.44% of its float.
ChartMill assigns a technical rating of 6 / 10 to ZBH. When comparing the yearly performance of all stocks, ZBH turns out to be only a medium performer in the overall market: it outperformed 49.29% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ZBH. ZBH has an excellent profitability rating, but there are concerns on its financial health.
Over the last trailing twelve months ZBH reported a non-GAAP Earnings per Share(EPS) of 7.93. The EPS increased by 1.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.51% | ||
| ROA | 3.6% | ||
| ROE | 6.57% | ||
| Debt/Equity | 0.54 |
35 analysts have analysed ZBH and the average price target is 114.98 USD. This implies a price increase of 11.6% is expected in the next year compared to the current price of 103.03.
For the next year, analysts expect an EPS growth of 2.98% and a revenue growth 7.24% for ZBH